

Sue J. Goldie

CURRICULUMVITAE

PROFESSIONAL ADDRESS:

Harvard T.H. Chan School of Public Health

Center for Health Decision Science
718 Huntington Avenue, 2nd floor
Boston, MA 02115
617-432-2010

Global Health Education and Learning Incubator at Harvard University

104 Mt. Auburn Street, 3rd floor
Cambridge, MA 02138
617-495-8222
sue_goldie@harvard.edu

PLACE OF BIRTH: Washington, D.C.

CITIZENSHIP: U.S.A.

SPOUSE: Aaron B. Waxman, MD, PhD

EDUCATION

1984	BS	Union College (Biology/Chemistry)
1988	MD	Albany Medical College
1997	MPH	Harvard School of Public Health

POSTDOCTORAL TRAINING

1996-98	Fellow, Agency for Health Care Research and Quality, Harvard School of Public Health
1988-91	Residency, Medicine, Yale New Haven Hospital, Yale University School of Medicine

LICENSURE AND CERTIFICATION

1989	Board Certification, National Board of Medical Examiners
1992	Board Certification, American Board of Internal Medicine
1998	Active Licensure, State of Massachusetts

ACADEMIC APPOINTMENTS

2014	Director, Global Health Education and Learning Incubator at Harvard University
2014	Special Adviser to the Provost on Global Health Education and Learning
2010	Professor of Global Health and Social Medicine, Harvard Medical School
2010-14	Faculty Director, Harvard Global Health Institute, Harvard University
2008	Roger Irving Lee Professor of Public Health, Harvard School of Public Health

2008 Director, Center for Health Decision Science, Harvard School of Public Health
2006 Professor of Health Decision Science, Harvard School of Public Health
2006 Director, Program in Health Decision Science, Harvard School of Public Health
2002 Associate Professor of Health Decision Science, Harvard School of Public Health
2001 Member of the Faculty of Arts and Sciences, Harvard University
1998 Assistant Professor of Health Decision Science, Harvard School of Public Health
1994 Assistant Clinical Professor of Medicine, Yale University School of Medicine
1991 Instructor of Medicine, Yale University School of Medicine

AWARDS AND HONORS

2016 Human Outreach Project, Humanitarian Service and Leadership
2016 Afghanistan Journal of Public Health, Service Award
2013 Favorite Professor of the Year by Harvard Class of 2013
2012 Favorite Professor of the Year by Harvard Class of 2012
2011 Faculty Mentoring Award, Harvard School of Public Health
2010 Alpha Omega Alpha Honor Medical Society Visiting Professorship
2009 John Eisenberg Award for Translation of Research to Practice
2009 Elected to the Institute of Medicine, National Academy of Sciences
2008 Roger Irving Lee Endowed Chair, Harvard School of Public Health
2006 Everett Mendelsohn Excellence in Mentoring Award, Harvard University
2005 MacArthur Fellow “Genius Award”
2005 Distinguished Alumni Award, Albany Medical College
2004 Harvard School of Public Health Excellence in Mentoring Award
2004 Outstanding Paper of the Year, Society for Medical Decision Making
2001-10 Teaching Excellence Commendation, Harvard School of Public Health
1998 Lawrence Linn Award, Society of General Internal Medicine
1997 Outstanding Educator Award, Yale School of Medicine, Quantitative Methods
1995 Original Investigation Competition Award for Innovative Programs in Medical Education, American Program Directors Internal Medicine

1988 The Frederick McCandless Prize
1988 The Neil Hellman Prize
1988 Janet M. Glasgow Memorial Achievement Award
1987 Alpha Omega Alpha Honor Medical Society
1984 Charles P. Drumm and Harold C. Wiggers Merit Scholar
1988 The Robert M. Fuller Medical Award
1984 The Leo and William Wrubel Memorial Prize
1981-84 Dana Fellowship Award, Charles A. Dana Foundation

HOSPITAL APPOINTMENTS

1991-97 Attending Physician, Yale New Haven Hospital, New Haven, CT
1992-96 Medical Director, Yale New Haven Hospital-Affiliated Saint Raphael
1994-96 Associate Program Director, Yale New Haven Hospital-Affiliated Saint Raphael, Internal Medicine Training Program

COMMITTEE ASSIGNMENTS

2016- Standing Committee on Appointments, Reappointments, and Promotions (SCARP), Harvard T.H. Chan School of Public Health

2013-16 Steering Committee, South Asia Institute, Harvard University
2013- The Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at the Harvard Law School, Affiliated Faculty
2013-16 Executive Committee, Harvard Committee on African Studies, Harvard University
2012- President's Innovation Fund for International Experiences, Harvard University
2011-12 Harvard University Provost Search Committee, Harvard University
2011-16 Senior Strategic Advisor, Steering Committee, Women and Health Initiative, Harvard T.H. Chan School of Public Health
2011- Instructional Program Committee on Global Health and Health Policy Secondary Field
2010-2015 Steering Committee for the Harvard Humanitarian Initiative, Harvard University
2010- Advisory Board for the Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health
2010-15 Steering Committee for Comparative Effectiveness Research Initiative, Harvard T.H. Chan School of Public Health
2002- Committee on Higher Degrees in Health Policy, Harvard University
2009-11 Committee Chair for Global Health Review, Harvard School of Public Health Dean
2007-09 Co-Chair [with Provost], Executive Committee, Harvard Initiative for Global Health
2007-08 Harvard School of Public Health Dean Search Committee, Harvard University
2006-07 Harvard Medical School Dean Search Committee, Harvard University
2006-10 Standing Committee on Global Health, Harvard University
2005 Task Force and Committee on Women Faculty, Harvard University
2003-05 Vice Chair, Faculty Council, Harvard School of Public Health
2002-03 Educational Committee for Curriculum Review, Harvard School of Public Health

PROMOTION AND APPOINTMENT COMMITTEE ASSIGNMENTS

2013-14 Jr. Faculty Global Health (GHP) Search Committee, Harvard School of Public Health
2013-14 Chair, Decision Science (HPM) Search Committee, Harvard School of Public Health

REGIONAL, NATIONAL, INTERNATIONAL COMMITTEES

2012-15 Commissioner, The Lancet Commission on Investing in Health
2012-13 Member, Lasker Foundation Cervical Cancer Initiative
2011- Advisory Board Member, Global Health Frontline News
2010-15 Governing Board, Chronic Diseases Initiative in Africa
2004-10 Expert Advisory Committee for Evidence-Based Vaccine Introduction for Latin American and Caribbean countries, Pan American Health Organization
2004-10 Board on Global Health, Institute of Medicine
2006-08 Committee on Economic Analysis for Vaccine Introduction, Pan American Health Organization
2006-07 National Cancer Institute Working Group: Health Services Research Agenda on Emerging Cellular, Molecular, and Genomic Technologies
2005-10 International HPV Vaccine Experts Forum, World Health Organization
2005-09 American Cancer Society Guideline Expert Panel on HPV Vaccination
2005-06 Co-Chair, Reproductive Health in Developing Countries, Global Health Council
2004-06 Global Diagnostics Forum, Bill and Melinda Gates Foundation
2003-04 Technical Advisor, Department of Reproductive Health and Research, World Health Organization

- 2003-05 Disease Control Priorities Project—World Bank, World Health Organization, Fogarty International Center at NIH, and the Gates Foundation
- 2003-06 Advisory Board Member, Sentinel Surveillance Site Committee for HPV, sponsored by the Centers for Disease, Control and Prevention
- 2002-03 Task Force Committee for American Cancer Society, Development of National Guidelines for Screening
- 2001-03 Alliance for Cervical Cancer Prevention to the World Bank (2001, 2002) and Gates Foundation (2003) Reproductive Health Program, DC
- 2001-03 International Expert Panel for the German Health Technology Assessment Series, Technical Advisor, German Federal Ministry of Health
- 2002 Committee for Planning Clinical Studies of HIV Disease in Developing Countries, National Institutes of Health
- 2002 ASCCP National Consensus Committee on Cervical Cancer Screening Guidelines, National Cancer Institute
- 2001 National Committee for Guideline Development for Prevention of HIV and AIDS-Related Opportunistic Infections, U.S. Public Health Service-Infectious Diseases Society of America (USPHS-IDSA)
- 2001 American Cancer Society Working Committee for the Development of U.S. National Screening Guidelines
- 2001 Elected Trustee, Society for Medical Decision Making
- 2000 Chairperson, Scientific Review Committee, Society for Medical Decision Making
- 1998 External Panel on Prevention of HPV Infection, National Committee on Research Priorities, Centers for Disease Control and Prevention
- 1999 USPHS-IDSA National Committee for Guideline Development for Prevention of HIV and AIDS-Related Opportunistic Infections, Bethesda, MD
- 1998 Nominations Committee, Society for Medical Decision Making
- 1995 Decision Science Curriculum Committee, Society for Medical Decision Making
- 1995 Regional Statewide Collaborative Education Planning Committee, Yale School of Medicine/University of Connecticut School of Medicine
- 1995 Regional Spring Scientific Session, Chair, American College of Physicians, Connecticut Chapter Associates Committee
- 1994 Residency Training Committee, Chair, Saint Raphael Hospital, Yale School of Medicine

PROFESSIONAL SOCIETIES

- 2016- American Public Health Association
- 2009- Institute of Medicine, National Academy of Sciences (elected 2009)
- 2008- Wilderness Medical Society
- 1995- Society of Medical Decision Making
- 1994-96 American Program Directors Internal Medicine
- 1994-00 Society of General Internal Medicine
- 1992-08 American College of Physicians
- 1987- Alpha Omega Alpha Honor Medical Society (elected 1987)

NON-PROFIT BOARDS

- 2007-17 Human Outreach Project, Board Chair
- 2014 Global Health Frontiers, Cielo Global Health Media, Board of Directors

2006-14 Management Sciences for Health (MSH), Director

PEER-REVIEWER/ EDITORIAL BOARD

JAMA; Annals of Internal Medicine; New England Journal of Medicine; Lancet; Medical Decision Making; Clinical Infectious Diseases; British Medical Journal; Afghanistan Journal of Public Health; Vaccine; Journal of Acquired Immune Deficiency Syndrome; Sexually-Transmitted Diseases; AIDS; Pharmacoeconomics; Health Economics; American Journal of Public Health; Cancer; Journal of National Cancer Institute; Archives of Internal Medicine; American Journal of Medicine; International Journal of Cancer. Editorial Boards: Medical Decision Making (2000-2003); Population Health Metrics (2006-2009)

FUNDING INFORMATION

Date: 04/1/07-12/31/16

Sponsor: John D. and Catherine T. MacArthur Foundation, 10-97002-000-INP

Role: Principal Investigator

Project: Global Maternal Morbidity and Mortality Policy

The objective of this project is to promote evidence-based decision making in a global effort to reduce maternal morbidity and mortality. With 99% of maternal deaths occurring in developing countries, we have adapted our Global Maternal Morbidity and Mortality Policy Model to India, Mexico, Afghanistan and Nigeria; we synthesize the best available data, incorporate real-world barriers and constraints to health service delivery, and conduct influential policy analyses that can iteratively guide decision making on phased approaches that are feasible, cost-effective and will assist countries in meeting Millennium Development Goal (MDG) 5 by 2015.

Date: 04/31/06-04/31/16

Sponsor: National Institutes of Health, R37 AI042006

Role: Co-Investigator

Project: Cost-Effectiveness of Preventing AIDS Complications

The purpose of this project is to synthesize the best available health and economic data to comparatively assess the health consequences, and cost-effectiveness of different strategies for managing HIV disease in the U.S. and to evaluate policy alternatives for the delivery of equitable care in HIV-infected patients. Questions of focus range from clinical decision making about tradeoffs between acute and chronic disease management, applicability of gender-based guidelines, disparities in access and treatment, and iterative assessment of when to start, stop and switch antiretroviral treatment regimens.

Date: 07/01/04-06/30/13

Sponsor: National Institutes of Health, R01 AI058736

Role: Principal Investigator, Subcontract

Project: Optimizing HIV Care in Less Developed Countries

The purpose of this project is to synthesize the best available health and economic data to develop a comprehensive state-transition model of the natural history and treatment of HIV disease in Ivory Coast, India and South Africa. This model is utilized to analyze country-specific data to determine the clinical impact, cost and cost-effectiveness of different strategies for opportunistic infection prophylaxis, tuberculosis preventive therapy, and antiretroviral use in each of these countries, and to develop country-specific treatment guidelines. In addition to comparative analyses of different clinical practice alternatives, assessed in the context of country-specific factors, we evaluate alterna-

tive policies for treatment eligibility and provision of equitable access to care to inform international stakeholders and decision makers.

Date: 12/01/04-12/31/12

Sponsor: Bill and Melinda Gates Foundation

Role: Principal Investigator

Project: Global HPV Vaccine Policy

The objective of this project is to promote evidence-based decision making in a global effort to prevent cancer mortality from a preventable disease which disproportionately affects women in poor countries; we aim to catalyze global cancer prevention efforts by synthesizing the best available data to identify effective, cost-effective, and affordable strategies to prevent HPV infection using new vaccines, and to detect precancerous lesions at a treatable stage using new diagnostics. Country focus for empirically calibrated models includes India, China, Vietnam, Thailand, Uganda, Tanzania, Kenya, Mozambique, South Africa, and Peru, Brazil, Haiti, Chile; Regional focus includes policy analyses for the 72 GAVI-eligible countries, and the 33 Latin American and Caribbean countries. Evaluation of early introduction programs includes Uganda, Vietnam, Peru and India.

Date: 09/27/07-07/31/11

Sponsor: National Cancer Institute, R01 CA093435

Role: Principal Investigator

Project: Clinical and Cost-effectiveness of HPV Vaccination in the US

The purpose of this project is to refine our empirically calibrated national prevention model of HPV transmission and cervical carcinogenesis. Integrating modules capable of assessing a wide range of strategies, we utilize the best available and most up to date data to assess the costs, benefits, and cost-effectiveness of primary prevention (vaccination), secondary prevention (screening), and strategies that combine both. This model is calibrated to the United States population using the best available data, including observed patterns in HPV type-specific prevalence, invasive cancer, and temporal variation in factors such as sexual behavior, parity, and smoking use. Heterogeneities ranging from those related to HPV-type-specific infection, to those associated with racial and ethnic subgroups are modeled. We use this analytic framework to assess the cost-effectiveness of alternative cervical cancer prevention strategies using a validated population-based simulation model linked to a dynamic transmission model – we identify optimal guidelines for both the general U.S. population as well as for subgroups that differ in their socioeconomic, demographic, and cervical cancer risk profile.

Date: 07/01/05-06/30/10

Sponsor: Bill and Melinda Gates Foundation, ID1200

Role: Co-Investigator

Project: Grand Challenges #13: Population Health Metrics Research Consortium

The purpose of this project is to develop new technology for population health measurement. Our research plan is predicated on five observations. First, critical information on population health needed to inform planning, resource allocation, program implementation, monitoring and evaluation includes at a minimum the prevalence and incidence of major diseases, prevalence of risk factors, mortality rates by cause, and effective coverage. Second, developments to measure population health must be rooted in a realistic understanding of affordable and feasible data collection platforms in low resource settings. Third, the challenge of measuring population health is fundamentally different than improving clinical diagnosis. Fourth, given priority needs for health information, there are some major gaps in the available measurement methods and technologies. Fifth, efforts to improve the

methods and technologies for population health measurement share a set of methodological challenges and empirical needs.

Date: 09/01/06-08/31/10

Sponsor: Agency for Healthcare Research and Quality, HSO15570

Role: Principal Investigator, Subcontract

Project: Disparities in Cancer Prevention and Control

The purpose of this project is to extend our current work on the development of decision-analytic policy models in cancer to incorporate the effects of disparities in screening, follow-up, and treatment and examine their impact on cancer-related outcomes. Traditionally, cost-effectiveness models focus on maximizing the health of a population (subject to resource constraints) and do not explicitly address distributional issues of who receives the costs or benefits. This proposal will rely on a highly collaborative and cross-disciplinary approach, integrating health decision science, epidemiology and biostatistics, healthy policy and ethical analysis. Using an integrative approach of decision science and ethical analysis, we will employ these simulation models to address socially relevant policy questions that disproportionately affect certain segments of the population.

Date: 05/01/07-04/30/08

Sponsor: PATH/Gates Foundation GAT.1246-04-07453-SUB

Role: Principal Investigator

Project: Impact Assessment of the HPV Vaccine for the GAVI Investment Case

The purpose of this project was to supervise a research associate conducting additional analysis of the cost-effectiveness of HPV vaccination strategies to support the GAVI investment case.

Date: 1/1/05-07/01/06

Sponsor: John D. and Catherine T. MacArthur Foundation

Role: Principal Investigator

Project: Global Maternal Morbidity and Mortality Policy Model, Mexico, Nigeria and India

The purpose of this project is to develop a model that would serve as an analytic framework and durable policy tool for use in different countries by public health and regional health care delivery decision makers and that would help key stakeholders understand and assess the costs and benefits of different strategies for reducing disability and death due to pregnancy-related complications.

Date: 05/07/02-02/28/06

Sponsor: National Cancer Institute, Ro1 CA93435-01

Role: Principal Investigator

Project: Cost-Effectiveness of Strategies to Reduce Global Mortality from Cervical Cancer

The purpose of this project is to develop a Global Cervical Cancer Policy Model to assess different cervical cancer control strategies in both developed and developing countries. The specific aims are to develop a model of human papillomavirus and its sequelae (cervical cancer) incorporating new epidemiological data; to evaluate the health and economic consequences of alternative screening strategies in the U.S; and to assess the cost-effectiveness of alternative screening and prevention strategies for previously unscreened women in South Africa and Zimbabwe.

Date: 11/1/04-10/31/05

Sponsor: PATH and the Bill & Melinda Gates Foundation

Role: Principal Investigator

Project: Technology Assessment HPV, China and India

The development of simple, rapid, accurate, safe, and inexpensive biochemical tests is a critical step in reducing the considerable gap in cervical cancer prevention between women in rich and poor countries. The purpose of this project is to develop a cost-effective screening method for cervical cancer that will be used primarily by women in resource-limited areas of the developing world. The cost-effectiveness analysis of alternative screening and treatment programs to plan effective cervical cancer prevention programs will accommodate relative cost differences of screening tests, technical requirements, infrastructure and program feasibility for China and India.

Date: 03/01/02-02/29/05

Sponsor: Bill and Melinda Gates Foundation

Role: Principal Investigator

Project: Modeling Cancer Prevention Strategies in Kenya, South Africa, Thailand, Peru, India

The purpose of this project is to develop a five analytic natural history and screening models representing 5 countries in different world regions. We will work with a team “on the ground” in each of the chosen countries to collect the necessary health economic and public health data needed to parameterize the models and conduct the analyses. The goal is to provide an analytic tool that may be used by health care planners to set up cervical cancer control services in developing countries.

Date: 10/1/03-03/31/05

Sponsor: Doris Duke Charitable Foundation (The Clinical Interfaces Award)

Role: Principal Investigator

Project: Multidisciplinary Approach to Understanding the Role of Social, Economic, and Immunological Factors in Cervical Cancer

This project will investigate the interface between factors such as nutrition, poverty, and co-morbid infections with the natural history of cervical cancer in an impoverished region of rural Haiti. It involves four core teams each representing a distinct discipline, namely clinical medicine, anthropology, decision science, and immunology.

Date: 08/01/02-07/31/03

Sponsor: National Institute on Alcohol Abuse & Alcoholism, R01 AA13216

Role: Principal Investigator, Subcontract

Project: Clinical Impact of HCV and Alcohol in HIV-Infected Persons

The purpose of this project is to test whether alcohol consumption and HCV, separately and together, are associated with worse HIV-related disease outcomes, and to determine the magnitude and importance of the effects. Our role is to develop the model to piggyback to the cohort study, to guide data collection efforts and instrument development, and to conduct a policy analysis that extends the findings from the clinical trial.

Date: 10/01/04-09/30/05

Sponsor: Centers for Disease Control and Prevention, U64/CCU 119525-01

Role: Principal Investigator, Subcontract

Project: Cost-effectiveness of Prophylaxis for AIDS-Related Infections: US and Africa

The purpose of this project is to evaluate the cost-effectiveness of new strategies for prophylaxis of opportunistic infections in sub-Saharan Africa. Our role in this project is to assess the cost-effectiveness of antiretroviral therapy in Cote d’Ivoire.

Date: 09/01/04-12/31/06

Sponsor: Mexican National Institute of Health and Ministry of Health

Role: Co-Investigator

Project: Mexico: Analytics for Priority Setting

The research included in this project is a necessary prerequisite for laying a strong foundation for a comprehensive and evidence-based analytic framework to guide development of Mexico's future health system, including efficient allocation of resources, and investments in new technology in the short-, medium-, and long-term. Key objectives of the research include: Undertaking collaborative research on disease-specific modeling, technology assessment, and cost-effectiveness analysis.

Date: 10/01/00-09/30/04

Sponsor: DHHS/CDC, U64/CCU 119525-01

Role: Principal Investigator, Subcontract

Project: Cost-effectiveness of Prophylaxis for AIDS-Related Opportunistic Infections in Cote d'Ivoire

The purpose of this project was to evaluate the cost-effectiveness of new strategies for prophylaxis of opportunistic infections in sub-Saharan Africa.

Date: 10/01/06-03/31/09

Sponsor: Center for Disease Control, 1406-04-07-CT-66327

Role: Principal Investigator

Project: Estimating the Impact and Cost-Effectiveness of Vaccination Strategies in the US for the Department of Health and Human Services, Center for Disease Control

The purpose of this project is the development, analysis and validation of models of the impact of HPV vaccination in the U.S. with specific analyses conducted to inform U.S. policy decisions on vaccine introduction and recommendations made by the ACIP

TRAINING GRANTS

Date: 06/01/09-6/30/20

Sponsor: National Institutes of Allergy and Infectious Diseases (T32AI007535)

Project: Epidemiology of Infectious Disease and Biodefense

Principal Investigator: George Seage III

Role: Advisor to pre doctoral students supported by this training grant

Date: 09/08/92-08/31/19

Sponsor: National Cancer Institute (R25CA057711)

Project: Harvard Education Program in Cancer Prevention Control

Principal Investigator: Glorian Sorensen

Role: Advisor to post doctoral students supported by this training grant

Date: 09/30/94-06/30/18

Sponsor: Agency for Healthcare Research and Quality (T32HS000055)

Project: Health Policy Training Program (NRSA)

Principal Investigator: Joseph Newhouse

Role: Advisor to pre doctoral students supported by this training grant

Date: 09/01/02-08/31/17

Sponsor: National Cancer Institute (R25CA092203)

Project: Program in Cancer Outcomes Research Training (PCORT)

Principal Investigator: Scott G. Gazelle

Role: Advisor to pre and post doctoral students supported by this training grant

Date: 09/30/92-06/30/17

Sponsor: National Institutes of Allergy and Infectious Diseases (T32AI007433)

Project: Program for AIDS Clinical Research (PACRT)

Principal Investigator: Kenneth Freedberg

Role: Advisor to pre and post doctoral students supported by this training grant

Date: 07/01/08-06/20/18

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR055885)

Project: Clinical and Outcomes Research in the Musculoskeletal Diseases

Principal Investigator: Jeffrey Katz

Role: Advisor to pre and post doctoral students supported by this training grant

Date: 07/01/76-06/30/17

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (T32DK007191)

Project: Research Training in Digestive Diseases

Principal Investigator: Raymond Chung

Role: Advisor to pre- and post doctoral students supported by this training grant

Date: 07/01/92-06/30/12

Sponsor: National Library of Medicine (T15LM007092)

Project: Biomedical and Health Informatics Research Training

Principal Investigator: Alexa T. McCray

Role: Advisor to two post doctoral students supported by this training grant

REPORT OF TEACHING

Harvard T.H. Chan School of Public Health

2017-current Decision Science for Public Health (RDS202). Course Instructor. New curriculum developed over 10 month period, includes methods and applications of decision analysis, decision trees, and probability revision; diagnostic tests and strategies, individual and population outcomes, and cost-effectiveness analysis in clinical and public health decision making. It is an online course that includes synchronous and asynchronous components composed of weekly multimedia lectures, problem sets, and interactive assignments, and assessment. 2017 - Class size is approximately 40-50 graduate students.

2015-current Fundamental Concepts of Public Health, Masters Course. Course Instructor. This course was designed as four core modules to provide students with a solid foundation as they start their education, experience and engagement in public health. Curriculum includes the conceptual framework for critically thinking about population health and the ability to use this framework as a platform from which to understand, contextualize, analyze, and tackle important public health challenges. 2015 co-taught with Dean Julio Frenk. 2016 taught as sole instructor. Class size approximately 500 Masters

Students.

- 2014-2015** **DrPH Fundamental Concepts of Public Health (GHP556).** Course Co-Instructor with Dr. Julio Frenk and Dr. Suerie Moon. Curriculum includes the conceptual framework for critically thinking about population health, health conditions, social determinants of health and societal responses. Class size is approximately 40 DrPH students.
- 1998-2012** **Decision Science for Health (RDS280).** Course Instructor. Curriculum covers problem assessment using a decision analytic framework, elements of a decision analysis, probability and Bayes theorem, diagnostic test performance, model structure, utility assessment, valuation of outcomes, cost-effectiveness analysis, introduction to advanced modeling methods, and uncertainty analysis. Context and cases are based on public health problems. Prior to 1998 there were approximately 40 students enrolled, by 2000 - 100 students; by 2006 -130 students, and by 2009 - 210 students. Course evaluations 6.0 and 7.0 (scale 0 to 7) 1998-2007, and average 4.6 (scale 0 to 5) 2008-2010.
- 1998-2000** **Practicum in Decision Science and Cost-Effectiveness Analysis (HPM289cd).** Co-Instructor. Curriculum covers advanced modeling methods including Monte Carlo simulation. Practical skills include use of decision analytic software. Students learn how to conceptualize a clinical or public health problem using a decision analytic framework, and work on their own projects over the semester with structured mentoring. Course evaluations between 6.0 and 7.0 (scale 0 to 7).

Harvard University

- 2010-current** **Societies of the World 24: Global Health Challenges: Complexities of Evidence-based Policy.** Spring Semester, Harvard University Faculty of Arts and Sciences. This course introduces the global health challenges posed by failure to adequately reduce infections, malnutrition, and maternal-child health problems in the most vulnerable populations, escalating rates of non-communicable diseases/injuries, and emerging health risks that cross national boundaries. We will assess social responses to these challenges at the community, national, and global levels. Through an understanding of population health measures, we will examine patterns of disease/mortality between and within countries, capture important time trends, and identify determinants of health inequalities. While emphasizing science driven policy, comparative case examples will illuminate influential systemic factors, health system performance, and the economic, social and political climate.
- 2017-current** **SSCI-E124: Global Health Challenges. Harvard Extension School.** Course Instructor. Curriculum is designed to emphasize broad analytic and critical thinking skills rather than acquisition of facts and details. Offered online with recorded lectures from the Harvard Faculty of Arts and Sciences course, “Societies of the World 24” and provides online weekly section. This course offers a broad conceptual foundation for critically thinking about population health in a global context, positioning health as a social objective that contributes to human development, human rights, and global security while exploring health conditions, health determinants operating within and beyond borders; and societal responses to health challenges. Health indicators, population metrics, and graphics are used to analyze the magnitude, distribution, and

trends of disease patterns and population dynamics across and within countries, with particular attention to the contemporary challenges of widening inequities, forced migration, displaced populations, and rapid urbanization. 2017 ~ 50 students.

- 2017-current HarvardX MOOC SW47.1x: Entrepreneurship and Healthcare in Emerging Economies.** Fall Semester, Harvard University Faculty of Arts and Sciences. The primary objective of the course is to engage students in the modern day health challenges affecting emerging economies, with a particular focus on the countries of South Asia, and to examine a range of entrepreneurial attempts to solve these problems. We hope that you will leave this course with a deeper understanding of the ways in which entrepreneurial action can effectively tackle major problems in South Asia, by combining knowledge of historical causes, qualitative and quantitative evidence, and context-specific knowledge of the commonalities and differences across South Asian countries. No prior knowledge of entrepreneurship, healthcare, or South Asia is required.
- 2013, 2014 Societies of the World 47: Contemporary South Asia: Entrepreneurial Solutions to Intractable Social and Economic Problems, Module IV Health.** Fall Semester, Harvard University Faculty of Arts and Sciences. The course is designed for undergraduates as well as graduate students from all parts of the University. Provides framework for critically thinking about the health of people in South Asia, broadly inclusive of health conditions, social determinants and societal responses from within and outside the health sector. Entrepreneurial opportunities to improve health will draw on innovation from multiple disciplines and sectors, and will range from new technologies, to delivery of services, to instruments of policy, to institutional innovation. Examples in the readings and class from India, Bangladesh, Pakistan, Myanmar and Afghanistan illuminate important cross-cutting contextual factors that will vary by country.
- 2004-2005 Health of the Poor: Analytic Tools for Decision Makers,** Fall Semester (Freshman Seminar Series), Harvard University Faculty of Arts and Sciences. 15 weeks. Interactive curriculum revolves around discussion of real-world global health challenges and demonstrates that evidence-based analyses can inform prioritization of diseases and health areas to be targeted in poor countries; students are introduced to analytical methods and tools that researchers use to aid decision makers in evaluating, on a comparative basis, the magnitude of benefits and costs from interventions competing for limited resources.
- 2001-2008 Core Seminar in Health Policy.** Public Health Section Leader, Harvard University Doctoral Program in Health Policy (HCP 597 & 598). Class size approximately 15 students. 6-8 weeks Developed curriculum for the Public Health Section of the Core Seminar in 2001-02 and coordinated a new schedule of seminars. The curriculum has as its overriding objective to enable students to gain the skills to evaluate and break-down a global public health problem into its components and conceptualize the types of information required, the most appropriate analytical skills, and the strategies for change. Seminars include didactic material, case-based discussions, and interactive debates.

Yale University

- 1997 **Biostatistics and Quantitative Methods for Clinical Research.** Course Instructor. Yale University Physician Associate Program. Yale New Haven Hospital and Affiliates.
- 1997 **Quantitative Methods for Clinical Research.** Department of Pulmonary Critical Care. Yale University School of Medicine.
- 1995-96 **Medical Decision Making in Internal Medicine.** Faculty development course. Yale New Haven Hospital and Affiliates, Yale University School of Medicine.
- 1992-97 **Introduction to Clinical Medicine.** Preclinical Instructor. 1st year medical students, Yale University School of Medicine.
- 1992-97 **Primary Care Ambulatory/ Inpatient Medicine.** Clinical Preceptor. 2nd year medical students, Yale University School of Medicine; Co-Section Instructor for Palliative Care. 4th year medical students, Yale University School of Medicine.

Community

- 2016 **Teaching Math for Social Justice.** Instructor. 1 day workshop for high school students from Cambridge School of Weston. This workshop built on ideas, such as conditional probability, which CSW algebra teacher and Incubator collaborator Agnes Voligny had already introduced to her students, in order to model and encourage analytical thinking through real-world challenges in public health and global health. Students discussed health risks such as the Zika virus, and worked through probability exercises framed to cross disciplinary boundaries and extend their understanding beyond mathematics and into the realms of public policy, ethics, health, and decision analysis. 6 students. June 6, 2016.
- 2015 **Modular Mini-Course: Global Perspectives on Population Health.** Instructor. Three-session shared learning and teaching experience for faculty at Cambridge School of Weston. These three workshops were attended by a core group of 11 CSW faculty members, representing the science, math, art, history, English, and library/technology departments. They provided a broad conceptual foundation for critically thinking about population health in a global context, positioning health as a fundamental prerequisite for building strong societies, and as a social objective that has become critically relevant to economic development, national security, foreign policy, and a human rights agenda.

ADVISEES OR TRAINEES

Students

- Kelechi Weze, MD, MPH:** Harvard T.H. Chan School of Public Health. Doctor of Public Health candidate. Academic advisor. Analysis of Health Systems Frameworks.
- Zach Ward:** Doctoral Program in Health Policy (concentration decision science) Harvard University. Research advisor. Empirical Calibration of Mathematical Model for Maternal Mortality in India, Afghanistan, and Nigeria.
- Lyndon James:** Doctoral Program in Health Policy (concentration decision science) Harvard University. Secondary research advisor.

Fellows

- Anshul Kumar, PhD:** Postdoctoral pedagogy research fellow. Working on development and evaluation of educational materials and instructional models to build and strengthen public and global health learning. Primary advisor.

- Daniel Erim, MD, MS:** (Former) Postdoctoral fellow in global strategies to reduce maternal mortality with an emphasis in Nigeria. Recipient of funding from the MacArthur Foundation for a Global Maternal Mortality Policy Project (PI: Goldie). Primary advisor, Research advisor.
- Jennifer Yeh, PhD:** (Former) Postdoctoral fellow in cancer control. PhD in Health Policy, Harvard University, 2007. Gastric Cancer Prevention Policy: The Economic and Population Impacts of Helicobacter pylori Screening. Recipient of a training grant from the National Cancer Institute. Primary advisor, Research advisor, thesis committee chair.
- Delphine Hu, MD, MPH:** (Former) Policy analysis of chlamydial screening in U.S. women. Cost-effectiveness analysis of interventions to reduce maternal mortality and morbidity. Submitted an R01 to the CDC ASPH and received the highest priority and merit score from the study section; was not funded due to an unanticipated shortfall in available funding at the CDC that year. Research advisor.
- Janice Kwon, MD, MPH:** (Former) Masters Degree, Health Policy and Management, 2002. Efficacy and Cost-effectiveness of endometrial cancer treatment strategies. Research Advisor. Recipient of Award in Gynecological Cancer Research, Cancer Care Ontario and the London Health Sciences Centre. Current mentor on GCR award. Research advisor.
- Serena Koenig, MD:** (Former) Postdoctoral fellow, Infectious Diseases, Brigham, Department of Social Medicine. HIV treatment in developing countries. Recipient of T32 postdoctoral fellowship HIV/AIDS (2004-2005). Current mentor on K award.
- Julie Servoss, MD:** (Former) Postdoctoral fellow in hepatology and policy research. Cost-effectiveness of treatment for HCV in HIV-infected individuals; simulation of two recent clinical trials of new HCV treatment in coinfecting individuals. Research advisor.
- Karen Andersson, MD:** (Former) Postdoctoral fellow in hepatology and policy research. Strategies for hepatitis B and C in low income countries. Research advisor.
- Natalie Carvalho, PhD:** (Former) Harvard School of Public Health. Evaluation of alternative approaches to reducing childhood mortality using community-based strategies (Africa), and to reducing maternal mortality in Afghanistan. Thesis Committee Chair, Research advisor.

Junior Faculty

- Anna Sinaiko, MPP, PhD:** Assistant Professor of Health Economics and Policy, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health.
- Ankur Pandya, PhD:** Assistant Professor of Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health.
- Tom Gaziano, MD, MPH:** Assistant Professor of Cardiology, BWH, HMS; Assistant Professor of Health Policy and Management, Department of Health Policy and Management, HSPH
- Jennifer Yeh, PhD:** Associate Scientific Researcher, Boston Children's Hospital.
- Nicolas Menzies, PhD:** Assistant Professor of Global Health, Department of Global Health and Population. Harvard T.H. Chan School of Public Health.
- Djøra Soeteman, PhD:** Research Scientist. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health.

Past Advisees

- Paula Chu, PhD:** Doctoral Program in Health Policy, Harvard University. Development of family planning model for guidance of policy alternatives for young women in India. Strategies to reduce maternal mortality in India and Nigeria. Primary advisor, research advisor.
- Jeremy Goldhaber-Fiebert, PhD:** Health Policy Program, Harvard University. Decision-Analytic Approaches to Evaluating Prevention Policy Alternatives. Recipient of multi-year award

from the National Science Foundation. Primary advisor, research advisor, thesis committee chair. Current Position: Assistant Professor of Medicine, Department of Medicine, Stanford University School of Medicine.

Joshua Salomon, PhD: Health Policy Program, Harvard University. “Modeling the HIV epidemic in Africa; Development of a mathematical model of the hepatitis C epidemic in the U.S.; Impact of heterogeneity on cost-effectiveness analyses of screening and treatment for HCV in the U.S.”. Recipient of Outstanding Doctoral Thesis Award (2002). Current position: Professor of Global Health, Harvard T. H. Chan School of Public Health. Research advisor, thesis committee.

Bruce Schackman, PhD: Health Policy Program, Harvard University. HIV modeling and policy, measuring quality of life and patient preferences in HIV disease, impact of chronic toxicity on cost-effectiveness of antiretroviral therapy in HIV. Current position: Associate Professor of Public Health, Chief of the Division of Health Policy, Weill Medical College of Cornell University. Research advisor, thesis committee.

Jane Kim, PhD: Health Policy Program, Harvard University. Cervical cancer screening in U.S., Europe, Hong Kong, and developing countries. Modeling methods to simulate natural history of HPV and cervical cancer in Brazil. Recipient of traineeships from the National Cancer Institute and the National Library of Medicine. Recipient Lee Lusted Prize, SMDM (2002); First place award for best oral presentation, International HPV meetings, (2005). Primary advisor, thesis committee chair. Junior Faculty advisor. Current position: Professor of Health Decision Science, Harvard T.H. Chan School of Public Health.

Julia Aledort, PhD: Doctoral Program in Health Policy, Harvard University. Developing a policy model of gonorrhea; Cost-effectiveness analysis of alternative strategies for control of gonorrhea. Recipient of a two-year National Library of Medicine training grant (1999-2001), a Novartis Training Fellowship Award (2002), a Graduate Society Fellowship Award (2003), and an Eliot Dissertation Completion Fellowship (2004). Recipient of student research award, Lee Lusted Prize at SMDM (2003), best oral research presentation, ISPOR International (2002). Current position: Research Scientist at RAND. Research advisor, thesis committee.

Sorapop Kiatpongsan: Doctoral Program in Health Policy, Harvard University. Incorporation of horizontal equity in strategic planning for scaling up maternal mortality interventions; Empiric evaluation of alternative modalities for translation of analytic research on maternal mortality to policy. Research advisor.

Caroline Korves, ScD: Doctoral Program in Epidemiology, Harvard School of Public Health. Cost-effectiveness of screening blood supply for West Nile Virus. Research advisor.

Eve Wittenberg, PhD: Doctoral Program in Health Policy, Harvard University. Influence of qualitative attributes on preferences, development of a preference measurement instrument. Current position: Senior Research Scientist, Harvard T.H. Chan School of Public Health. Research advisor, thesis committee.

Phaedra Corso, PhD: Doctoral Program in Health Policy, Harvard University. Preference measurement, risk communication, preferences for prevention versus curative interventions Recipient of Lee Lusted Prize, National Meeting of Society for Medical Decision Making, (2002). Current position: Research Scientist at CDC. Research advisor, thesis committee.

David Fisman, MD: Infectious Disease Fellow, Beth Israel Hospital, AHCPR Fellow. Screening for herpes in monogamous couples, projecting the clinical and cost consequences of herpes in the US, health-related quality of life in patients with herpes. Three manuscripts published. Recipient of Glaxo Smithkline Young Investigator Award (2003) Current position: Assis-

tant Professor, Drexel University School of Public Health. Primary research advisor.

Feli Baldamu, MSc: Masters Program in Health Policy and Management, Harvard School of Public Health. Development of a simulation model of HCV and HIV, Exploratory analysis of the costs and clinical benefits of treating HCV in HIV. Primary advisor and research mentor.

Larissa Roux, MD, MPH: MPH Program. Cost-effectiveness analysis of interventions to decrease BMI in moderately obese women, quality of life in obese women 1 of 5 Finalists for the Ethan Sims Young Investigator Award, NAASO, Quebec. (2002) Research mentor.

Yun-Hsin (Claire) Wang: ScD in Health Policy Program, Harvard School of Public Health. Mathematical modeling of fluoroquinolone usage and fluoroquinolone-resistant pneumococci in the community. Current Position: Assistant Professor in the Department of Health Policy and Management at the Columbia Mailman School of Public Health. Research advisor, thesis committee.

Sun-Young Kim: Doctoral Program in Health Policy, Harvard University. Cost-effectiveness and affordability of HBV vaccination in the Gambia. Recipient of the Novartis Training Fellowship Award. Research advisor, thesis committee. Current Position: Assistant Professor, University of Texas School of Public Health.

Chara Rydzak, MD, PhD: Combined MD/PhD Program, Harvard University. Control measures for syphilis in high-risk populations in South Africa for rapid syphilis testing: cost-effectiveness of new technology; Mental health burden of disease among women in developing countries. Recipient of a training grant from the National Institute for Mental Health. Current Position: Resident, Department of Radiology, Hospital of the University of Pennsylvania. Primary advisor, thesis committee chair.

April Kimmel, PhD: Doctoral Program in Health Policy, Harvard University. Cost-effectiveness of technologies for HIV treatment; Analytic framework for operational delivery of equitable ART in developing countries. Harvard School of Public Health. Current Position: Assistant Professor, Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine. Research Advisor.

Nicole Gastineau Campos: Doctoral Program in Health Policy, Harvard University. Evaluation of alternative approaches to reducing HPV-related mortality in 5 East African countries, and analysis of predictors of type-specific HPV persistence using empiric data. Charles Wilinsky Award, Harvard School of Public Health. Thesis committee chair, primary advisor.

Rebecca Anhang Price: Doctoral Program in Health Policy, Harvard University. Preferences for screening, focus groups and qualitative methods for women's health, content analysis; development of a tool to elicit women's preferences in China for new cervical cancer screening technology. Research advisor, thesis committee. Current Position: Policy Analyst, RAND Corporation.

Christina Dias: Master of Liberal Arts program, Harvard Extension School. Compulsory Primary Education and the Intergenerational Transfer of Debt Bondage in the Indian Agricultural Sector. Thesis advisor.

Matthew Miller, MD, MPH, ScD: Professor of Health Sciences and Epidemiology, Director of Undergraduate Health Sciences Program, Northeastern University. Former Associate Professor of Health Policy, Department of Health Policy and Management, Harvard School of Public Health.

Tiara M. Forsyth: Harvard Medical School. Doctor of Medicine candidate. Reproductive health education efforts for women and girls in resource-limited, Muslim-majority settings, particularly Afghanistan. Scholarly Project Advisor.

Cynthia Tassopoulos: Harvard College. Challenges and opportunities of urbanization in Brazil.

Capstone research paper advisor.

Nigel Deen: Harvard College. Evaluation of alternative approaches to reducing maternal mortality in Sierre Leone. [Primary Advisor – S. Resch] Secondary Research Advisor.

Nina Bhattacharya: Harvard T.H. Chan School of Public Health. Master of Science candidate, Global Health & Population. Facilitators of Sustainable Women’s Cooperatives: An Analysis of Women’s Groups in Northern Tanzania. [Primary Advisor – J. Bump] Secondary Research Advisor.

Other

DrPH student cohort: Serves as an informal mentor to Chan School graduate students in the master’s and DrPH tracks who have participated in her “Fundamental Concepts of Public Health” orientation courses in 2015 and 2016. Between 10 and 15 master’s and doctoral students meet regularly at the Global Health Education and Learning Incubator to share ideas, develop research thinking, and explore innovative approaches to learning and teaching about public health. Several of these students have gone on to work as teaching fellows for SW24 and SSCI E124 spring 2017 courses.

Cambridge School of Weston senior faculty: Serves as an informal mentor to seven Cambridge School of Weston (CSW) faculty, who have collaborated with the Global Health Education and Learning Incubator to create an interdisciplinary curriculum on global and national health for high school students. The seven teachers collectively share 125 years of teaching experience in the subjects of mathematics, science, history, English, and visual arts. Goldie has worked most closely with art teacher Tom Evans and algebra teacher Agnes Voligny, both of whom have participated in intensive faculty immersion residencies under supervision at the Incubator.

SELECTED PRESENTATIONS

- 2017 Voices in Leadership: Webcast Discussion Series, featuring Dr. Suraya Dalil. Invited faculty moderator. Harvard T.H. Chan School of Public Health, Boston, MA. November 29, 2017.
- 2017 The Center for Health Decision Science and Global Health Education and Learning Incubator impact on the teaching and learning at the Chan School, Health Policy & Management Executive Council, Boston, MA. October 25, 2017
- 2017 “Speaking the Same Language”, invited special guest at the Methods and Case Studies workshop on benefit-cost analysis (BCA) in global health and development, held on November 2-3, 2017 at Harvard’s Joseph B. Martin Center.
- 2016 Teaching Math for Social Justice. Workshop for high school students from Cambridge School of Weston. Cambridge, MA. June 6, 2016.
- 2015 Modular Mini-Course: Global Perspectives on Population Health. Cambridge School of Weston. Weston, MA. January 14 & 21, March 4, 2015.
- 2015 CFAR Urban Youth Graduation. Keynote Speaker. Cambridge, MA. May 6, 2016.
- 2015 Cost-effectiveness analysis at Harvard. Economic Evaluation in health: Cost Effectiveness and Beyond conference. Boston, MA. September 15- 17, 2015.
- 2015 Invited presentation on Global Health and Health Policy. Overseers Standing Committee on Social Sciences. Harvard University. March 29, 2015.
- 2014 Global learners, global learning: characteristics and pedagogies. Association of American Colleges and Universities (AAC&U) Global Learning in College: Cross-Cutting Capacities for 21st Century College Students. Keynote Address. October 16, 2014.

- 2014 Global public health in transition – opportunities for entrepreneurial innovation. Harvard Business School Innovations in Global Health Care (“BIG”). June 26, 2014.
- 2013 The Second Century Symposium: Transforming Public Health Education. Harvard School of Public Health. November 1, 2013.
- 2013 Emerging Agendas in Global Health Symposium. Harvard University. October 2, 2013
- 2013 Global health delivery systems. Global Advisory Council. Harvard University. September 20, 2013.
- 2013 Measuring and evaluating health and development. GHP@50 Global Health Symposium. Harvard School of Public Health. April 25, 2013.
- 2013 Global health challenges and opportunities. Harvard University Board of Overseers Meeting. Harvard School of Public Health. February 3, 2013.
- 2012 New ways of thinking: financing decision-making and resource allocation. Harvard Ministerial Health Leaders’ Forum. Harvard Kennedy School of Government. June 5, 2012.
- 2012 A global perspective on maternal mortality: analysis, advocacy and action. Second Annual Beatrice L. Pitcher, MD Lecture. Brigham and Women’s Hospital. Boston, MA. April 17, 2012.
- 2011 Health as a global concern. HSPH Leadership Council on Global Health Security. October 21, 2011.
- 2011 World health: global concern and university priority. Harvard Business School. September 24, 2011.
- 2011 Insights from decision science about reproductive and maternal health: crossing disciplinary boundaries. Foundation Presidents Meeting on Population and Reproductive Health, MacArthur Foundation. Chicago, IL. May 17, 2011.
- 2011 Harvard PhD Health Policy Program. Harvard Law School. April 2011.
- 2011 Health and economic outcomes of strategies to reduce maternal morbidity and mortality. Faculty of Arts and Sciences and Harvard Global Health Institute. March 2011.
- 2010 John F. Kennedy, Jr. Forum Panel: Global Health Diplomacy. Harvard Kennedy School. December 6, 2010.
- 2010 Global health in the 21st century: challenges and opportunities. Grand Rounds, Albany Medical College. Albany, New York. November 11, 2010.
- 2010 Alpha Omega Alpha Visiting Professorship. Contextualizing policies to reduce maternal mortality. Albany Medical Center, Albany, NY. November 12, 2010.
- 2010 Global inequities in HPV vaccination: translating policy to action. Albany Medical College. Albany, New York. November 10, 2010.
- 2010 Prevention of cervical cancer: scientific success, public health failure. Harvard University, Faculty of Arts and Sciences. November 4, 2010.
- 2010 Sexually-transmitted diseases with an emphasis on HPV. Harvard School of Public Health. October 12, 2010.
- 2010 Clinical impact, economic consequences, and cost-effectiveness of strategies to reduce maternal mortality. Harvard University, Faculty of Arts and Sciences. April 2010.
- 2010 Health and economic impact of HPV 16 and 18 vaccination to prevent cervical cancer in low- and middle-income countries. HPV Vaccine Advisory Committee, WHO. Geneva, Switzerland. April 27-29, 2010.
- 2009 HPV costing workshop. ProVac: tools for evidence-based decision on new vaccines. Pan-American Health Organization. Kingston, Jamaica. July 20-21, 2009.
- 2009 Evidence-based decision making about the introduction of new vaccines: the case of HPV in

- the context of rotavirus. Bill and Melinda Gates Foundation. Seattle, WA. April 21, 2009.
- 2008 Cervical cancer prevention with prophylactic vaccines against HPV 16 and 18 infection: health and economic outcomes. HPV Vaccine Advisory Committee, WHO. Geneva, Switzerland. July 8, 2008.
- 2008 Cervical cancer prevention policy models in developed countries. HPV Regional Reports International Meeting. Barcelona, Spain. February 7, 2008.
- Cervical cancer prevention policy models in Latin America and the Caribbean. HPV Regional Reports International Meeting. Barcelona, Spain. February 8, 2008.
- Cervical cancer prevention policy models in Asia and the Pacific. HPV Regional Reports International Meeting. Barcelona, Spain. February 7, 2008.
- 2008 "Given limited resources, how can we save the most lives?" TED. Monterey, CA. February 29, 2008.
- 2007 Decision science to inform health policy: the public health paradigm of cervical cancer prevention. Grand Rounds, Hospital of Saint Rafael. New Haven, CT. May 29, 2007.
- 2007 Analysis, advocacy and action: applying a decision analytic framework to maternal mortality. Consultation on Global Safe Motherhood Strategy. Chicago, IL. May 16-17, 2007.
- 2007 Edward C. Hill Lecture, Clinical benefits, public Health Impact, and cost-effectiveness of cervical cancer prevention: decision science to inform health policy. University of California, San Francisco. San Francisco, CA. May 8, 2007.
- 2007 Decision science to inform health policy: the case of HPV infection and cervical cancer. Dana Farber Cancer Outcomes Research Seminar. Dana Farber Cancer Institute. Boston, MA. March 13, 2007.
- 2006 Using decision analytic methods to assess the benefits, costs, and cost-effectiveness of new technology for cervical cancer prevention. Developing a Health Services Research Agenda on Emerging Cellular, Molecular, and Genomic Technologies in Cancer Care, NIH. Washington, D.C. December 8, 2006.
- 2006 Public health benefits and cost-effectiveness of strategies for cervical cancer prevention: Decision Science to inform health policy. Women in Government HPV and Cervical Cancer Summit. Washington, D.C. November 16-18, 2006.
- 2006 Analytics to inform cervical cancer control policy. AACR Frontiers in cancer prevention research. Boston, MA. November 15, 2006.
- 2006 Phyllis T. Bodel Lecturer, Decision science to inform health policy: the case of HPV infection and cervical cancer. Yale School of Medicine. New Haven, CT. October 25-27, 2006.
- 2006 Economic framework for vaccine introduction of Latin American and Caribbean Countries. PRO-VAC vaccine workshop. Washington, D.C. September 7, 2006.
- 2006 Cost-effectiveness of cervical cancer control. Plenary Speaker. 2nd American Congress of Epidemiology. Seattle, WA. June 21-24, 2006.
- 2006 Global challenge of chronic diseases: using decision analytic methods to inform health policy. PATH. Seattle, WA. May 2006.
- 2005 Strategies to synergize efforts for an HPV vaccine in developing countries; Cost-effectiveness of HPV vaccine in Tanzania. World Health Organization. Geneva. April 2005.
- 2004 Potential impact of waning of vaccine-induced immunity against HPV 16/18: implications for public health. International Papillomavirus Conference. Mexico. February 2004.
- 2004 Cost-effectiveness of cervical cancer screening in Kenya, India, Peru, South Africa, and Thailand. International Papillomavirus Conference. Mexico. February 2004.
- 2004 Cost-effectiveness analysis to inform prioritization of vaccination and screening interventions. Bill and Melinda Gates Foundation. Seattle, WA. February 2004.

- 2004 Health and economic impact of new technology for cervical cancer control. Reproductive Health Division. World Health Organization. Geneva. February 10, 2004.
- 2003 Future health policy initiatives: exploring the cost-effectiveness of HPV vaccination to prevent cervical cancer. Symposium on Human Papillomavirus and Immunotherapies: University of Cambridge, England. July 10-13, 2003.
- 2003 Applying the tools of mathematical modeling and decision science to global health diagnostics. Global Health Diagnostics Working Group. Bill and Melinda Gates Foundation. Seattle, WA. May 5-7, 2003.
- 2003 A comprehensive health policy initiative in women's health: cancer screening in South Africa, Kenya, Thailand, India and Peru. Bill and Melinda Gates Foundation. February 17, 2003.
- 2002 Health policy for HIV and AIDS. Grand Rounds and Infectious Diseases Seminar Series. University of Alabama. November 18, 2002.
- 2002 Using methods of decision science to improve reproductive health of women in developing countries. Grand Rounds. Zanmi Lasante, Cange, Haiti. August 15, 2002.
- 2002 Planning clinical studies of HIV disease in developing countries: developing cost parameters and cost-effectiveness models. National Institutes of Health. Washington, D.C. February 2002.
- 2002 Analysis, advocacy and action. Cervical cancer screening and reproductive health policy in developing countries. Seminar at the Fogarty Center for International Health and Development. September 16, 2002.
- 2001 Designing vaccine efficacy trials for a prophylactic HPV vaccine trial: Using a mathematical model to evaluate surrogate endpoints." FDA. Washington, D.C. 2001.
- 2001 Developing HPV Screening Policy in Developing Countries. World Bank. Washington, D.C. 2001.
- 2001 Health economics and mathematical models; HPV testing in primary and secondary screening; cost-effectiveness of HPV vaccines. Global Challenges and Opportunities in Cervical Cancer Prevention. Nice, France. 2001.
- 2001 New approaches in the prevention of HPV and cervical Cancer. 19th International Papillomavirus Conference. Health Economics and the Prevention Strategies for HPV. Florianopolis. Santa Catarina. 2001.
- 2001 Cost-effectiveness of HPV and cervical cancer prevention strategies. Development of a policy model for the control of HPV in developing countries. Bill and Melinda Gates Foundation and the Alliance for Cervical Cancer Prevention. 2001.
- 2000 Using simulation modeling to develop screening policy for HPV in developing countries; Cost-effectiveness of screening using a single lifetime HPV test in South Africa. 18th International Papillomavirus Conference. Barcelona, Spain. July 2000.
- 2000 Using simulation modeling to develop screening policy for chlamydia trachomatis in US sexually active men and women. Center for Disease Control and Prevention. September 2000.
- 1998 Projecting the cost-effectiveness of screening for HPV-induced anal neoplasia in HIV-infected homosexual and bisexual men. World AIDS Conference, Geneva. 1998.
- 1998 Developing a model to incorporate longitudinal cohort data on the incidence and progression of HPV and cervical neoplasia. Center for Disease Control and Prevention. Atlanta, GA. 1998.
- 1997 Technology exchange: using risk and decision science modeling to understand HPV-induced neoplasia and subsequent cancer risk. Center for Disease Control and Prevention. Atlanta, GA. 1997.

- 1997 Projecting the societal costs and clinical benefits of screening for cervical neoplasia in HIV-infected women. University California San Francisco School of Medicine. San Francisco, CA. 1997.
- 1997 State transition modeling to extend the time horizon of clinical trials HIV epidemiology research study. Clinical Trial Rhode Island Site, Miriam Hospital. Providence, RI. October 1997.

Regional/National Continuing Medical Education Courses

- 1998-05 Core Faculty, Cost-Effectiveness Analysis for Medical Technology and Pharmaceuticals, Introduction to Advanced Modeling, Harvard School of Public Health.
- 1999 Course Instructor, 21st Annual Meeting for the Society of Medical Decision Making. Course Faculty, Advanced Methods in Decision Science, Reno, NV.
- 1998 Course Instructor, 20th Annual Meeting for the Society of Medical Decision Making. Pre-course Faculty, Advanced Methods in Decision Science, Boston, MA.
- 1996 Course Director and Instructor, 18th Annual Meeting, Society for Medical Decision Making, Integrating Medical Education and Medical Decision Making, Canada.
- 1995 Course Instructor, American Program Directors Internal Medicine National Meeting, Evaluating Clinical Competence, Atlanta, GA.
- 1995 Course Instructor, 17th Annual Meeting, Society for Medical Decision Making, Teaching Medical Decision Making, Tempe, AZ.

Teaching Awards

Harvard School of Public Health, Mentor Award (2011); Harvard University, GSAS Everett Mendelsohn Excellence in Mentoring Award (2006); Harvard School of Public Health, Mentor Award (2004); Letter from the Committee on Educational Policy for course evaluations 6.0-7.0 (scale 0 to 7), Harvard School of Public Health (1999-2009); Outstanding Educator Award, Yale School of Medicine, Quantitative Methods (1997); Original Investigation Competition Award for Innovative Programs in Medical Education, American Program Directors Internal Medicine (1995).

PUBLICATION BIBLIOGRAPHY

Original peer-reviewed articles

1. Goldie SJ, Kiernan L, Torres C, Gorban-Brennan N, Dunne D, Kliger A, Finkelstein F. Fungal peritonitis in a large chronic peritoneal dialysis population. *Am J Kidney Dis.* 1996; 28:86-91.
2. Troidle L, Kliger A, Goldie SJ, Gorban-Brennan N, Fikrig M, Brown E, Finkelstein F. Continuous peritonitis dialysis - associated peritonitis of nosocomial origin. *Peritonitis Dialysis International.* 1996;16:505-10.
3. Waxman AB, Goldie SJ, Brett Smith H, Matthay R. Cytomegalovirus as a primary pulmonary pathogen in AIDS. *Chest.* 1997; 111:128-34.
4. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of airbags by seating position. *JAMA.* 1997; 278:1418-25.
5. Paltiel AD, Scharfstein JA, Seage GR, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg, KA. A monte carlo policy model of advanced HIV disease: application to CMV prevention. *Med Decis Making.* 1998;18 Suppl:S93-S105.
6. Graham JD, Goldie SJ, Segui-Gomez M, Thompson KM, Nelson T, Glass R, Simpson A, Woerner LG. Reducing risks to children in vehicles with passenger airbags. *Pediatrics.* 1998; 102(e3).
7. Goldie SJ, Freedberg KA. Diagnosis and treatment of pneumocystis carinii pneumonia:

- economic issues and cost-effectiveness. *Seminars in Respiratory and Critical Care Medicine*. 1999; 20(3):213-20.
8. Macones GA, **Goldie SJ**, Peipert JF. Cost-effectiveness analysis in women's health. *Obstet Gynecol Surv*. 1999; 54:663-72.
 9. **Goldie SJ**, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. *Ann Intern Med*. 1999; 130:97-107.
 10. **Goldie SJ**, Kuntz KM, Weinstein MC, Freedberg KA, Welton M, Palefsky JM. The clinical-effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA*. 1999; 281:1822-9.
 11. Golden M, **Goldie SJ**. Epidemiology of *Pseudomonas aeruginosa* in HIV-infected patients. *Infect Med*. 2000; 17:109-116.
 12. **Goldie SJ**, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for HPV-induced anal squamous intraepithelial lesions in homosexual men. *Am J Med*. 2000; 108:634-41.
 13. Neumann PJ, **Goldie SJ**, Weinstein MC. Preference-based measures in economic evaluation in health care. *Annu. Rev. Public Health*. 2000; 21:1-25.
 14. Mrus JM, **Goldie SJ**, Weinstein MC, Tsevat J. The cost-effectiveness of elective cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. *AIDS*. 2000; 14:2543-52.
 15. Stone P, Teutch S, Chapman R, Bell C, **Goldie SJ**, Neumann P. Cost-utility analyses of preventive services. *Am J Prev Med*. 2000; 19:15-23.
 16. Wright TC, **Goldie SJ**, Cain JM, Howett MK. Screening for cervical cancer. *Science*. 2000; 290:1651.
 17. Freedberg KF, Losina E, Weinstein MC, Paltiel AD, Cohen C, Seage GR, Craven DE, Zhang H, Kimmel AD, **Goldie SJ**. The cost-effectiveness of combination antiretroviral therapy for HIV disease. *N Engl J Med*. 2001; 344:824-31.
 18. Weinstein MC, **Goldie SJ**, Losina E, Cohen CJ, Baxter J, Kimmel AD, Freedberg KA. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. *Ann Intern Med*. 2001; 134:440-450.
 19. Shireman TI, Tsevat J, **Goldie SJ**. Time costs associated with cervical cancer screening. *Int J Tech Assess in Health Care*. 2001; 17:146-152.
 20. Fisman DN, Reilly DT, Karchmer AW, **Goldie SJ**. Clinical and cost-effectiveness of two management strategies for infected total hip arthroplasty in the elderly. *Clin Infect Dis*. 2001; 32:419-430.
 21. Paltiel AD, **Goldie SJ**, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, Freedberg KA. A pre-evaluation of clinical trial data: the case of pre-emptive Cytomegalovirus therapy in human immunodeficiency virus. *Clin Infect Dis*. 2001; 32:783-793.
 22. **Goldie SJ**, Kuhn LK, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. *JAMA*. 2001; 285:3107-3115.
 23. **Goldie SJ**, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost-effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the Human Immunodeficiency Virus. *Am J Med*. 2001; 111:140-149.
 24. Zanetti G, **Goldie SJ**, Platt R. Clinical consequences and cost of limiting use of Vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. *Emerg Infect Dis*. 2001; 7:1-15.

25. Yazdanpanah Y, Chene G, Losina E, **Goldie SJ**, Merchadou LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in 2 HIV-infected French clinical cohorts. *Int J Epidemiol.* 2001; 30:864-871.
26. Schackman BR, **Goldie SJ**, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. *Am J Public Health.* 2001; 91:1456-1463.
27. **Goldie SJ**, Levin AR. Genomics in medicine and public health: role of cost-effectiveness analysis. *JAMA.* 2001; 286:1637-1639.
28. Wittenberg E, **Goldie SJ**, Graham JD. Predictors of hazardous child seating behavior in fatal motor vehicle crashes: 1990 to 1998. *Pediatrics.* 2001; 108:438-42.
29. Schackman BR, **Goldie SJ**, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. *Med Decis Making.* 2002; 22:27-38.
30. Yazdanpanah Y, **Goldie SJ**, Losina E, Weinstein MC, Lebrun T, Paltiel AD, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. *Antivir Ther.* 2002; 7:257-66.
31. **Goldie SJ**, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Kimmel AD, Zhang H, Freedberg KA. Prophylaxis for HIV-related pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. *Arch Intern Med.* 2002; 162:921-928.
32. Johri M, Paltiel D, **Goldie SJ**, Freedberg KA. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing standards. *Med Care.* 2002; 40:429-441.
33. Fisman DN, Lipsitch M, Hook EW, **Goldie SJ**. Projection of the future dimensions and costs of the genital herpes simplex Type 2 epidemic in the United States. *Sex Transm Dis.* 2002; 29:608-22.
34. Kuntz KM, **Goldie SJ**. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. *Med Decision Making.* 2002; 22:218-227.
35. Schackman B, Freedberg KA, Weinstein MC, Sax P, **Goldie SJ**. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. *Arch Intern Med.* 2002; 162:2478-2486.
36. Kim J, Wright TC, **Goldie SJ**. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance in the U.S.: A policy analysis. *JAMA.* 2002; 287:2382-2390.
37. Salomon J, Hammitt J, Weinstein M, **Goldie SJ**. Empirically calibrated model of hepatitis C virus infection in the United States. *Am J Epidemiol.* 2002; 156:761-73.
38. Corso PS, Hammitt JK, Graham JD, Dicker RC, **Goldie SJ**. Assessing preferences for prevention versus treatment using willingness to pay. *Med Decis Making.* 2002; 22:S92-101.
39. Walensky R, **Goldie S**, Losina E, Seage G, Paltiel AD, Freedberg K. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. *J Acquir Immune Defic Syndr.* 2002; 31:27-37.
40. Seage GR, Losina E, **Goldie SJ**, Paltiel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. *J Acquir Immune Defic Syndr.* 2002; 30:421-8.
41. **Goldie SJ**. Health economics and cervical cancer prevention: a global perspective. *Virus Res.* 2002; 89:301-309.

42. Kuehne F, Bethe U, Freedberg K, **Goldie SJ**. Treatment for hepatitis C virus in HIV infected patients: clinical benefits and cost-effectiveness. *Arch Intern Med*. 2002; 162:2545-56.
43. Fisman DN, Hook EW, **Goldie SJ**. Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognized infections with herpes simplex virus type 2. *Sex Transm Infect*. 2003; 79:49-52.
44. Yazdanpanah Y, **Goldie SJ**, Paltiel AD, Losina E, Coudeville L, Weinstein MC, Gerard Y, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of human immunodeficiency virus related opportunistic infections in France: A cost-effectiveness analysis. *Clin Infect Dis*. 2003; 36:86-96.
45. Yeh J, Hook E, **Goldie SJ**. A refined estimate of the average lifetime cost of pelvic inflammatory disease. *Sex Transm Dis*. 2003; 30:369-78.
46. **Goldie S**, Kuntz K. A potential error in evaluating cancer screening: a comparison of two approaches for modeling underlying disease progression. *Med Decis Making*. 2003; 23:232-41.
47. Wittenberg E, **Goldie SJ**, Fischhoff B, Graham JD. Rationing decisions and individual responsibility for illness: are all lives saved equal? *Med Decis Making*. 2003; 23:194-211.
48. **Goldie SJ**. Public health policy and cost-effectiveness analysis: HPV and cervical cancer. *J Nat Cancer Inst Monographs*. 2003; 31:102-110.
49. Salomon J, Weinstein MW, Hammitt J, **Goldie SJ**. Cost-effectiveness of treatment for chronic hepatitis C virus in an evolving patient population. *JAMA*. 2003; 290:228-237.
50. **Goldie SJ**, Grima D, Kohli M, Wright TC, Weinstein MC, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV 16/18 vaccine. *Int J Cancer*. 2003; 106:896-904.
51. **Goldie SJ**, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Wolensky R, Sax P, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. *Am J Med*. 2003; 115:632-41.
52. Anhang R, Stryker JE, Wright TC, **Goldie SJ**. News media coverage of HPV. *Cancer*. 2004; 100:308-14.
53. Anhang R, Wright TC, Smock L, **Goldie SJ**. Women's desired information about HPV. *Cancer*. 2004; 100:315-20.
54. **Goldie SJ**, Kim J, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. *Obstet Gynecol*. 2004; 103:619-31.
55. **Goldie SJ**, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. *J Natl Cancer Inst*. 2004; 96:604-615.
56. Wright TC, Schiffman M, Solomon D, Cox TJ, Garcia F, **Goldie SJ**, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. *Obstet Gynecol*. 2004; 103:304-9.
57. Chapman RH, Berger M, Weinstein MC, Weeks JC, **Goldie SJ**, Neumann PJ. When does quality-adjusting life years matter in cost-effectiveness analysis? *Health Econ*. 2004; 13:429-36.
58. Kim JJ, Leung G, Woo P, **Goldie SJ**. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. *J Public Health*. 2004; 26:130-7.
59. Anhang R, Goodman AK, **Goldie SJ**. HPV communication: review of existing research and recommendations for patient education. *CA Cancer J Clin*. 2004; 54:248-9.
60. Salomon J, Weinstein MW, **Goldie SJ**. Taking account of future technology in cost-effectiveness analysis. *BMJ*. 2004; 329:733-6.
61. Hu D, Hook E, **Goldie SJ**. Screening for chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. *Ann Intern Med*. 2004; 141:501-13.

62. Schackman BR, Oneda K, **Goldie SJ**. HCV cost-effectiveness of cesarean section to prevent HCV transmission in pregnant HIV-HCV co-infected mothers. *AIDS*. 2004; 18:1827-34.
63. **Goldie SJ**, Palefsky JM, Workowski K. Anal cancer in HIV infection: to screen or not to screen. *AIDS Clin Care*. 2004; 16:53-5,57.
64. Walensky R, Paltiel AD, **Goldie SJ**, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? *Vaccine*. 2004; 22:4044-4053.
65. Smith Fawzi, MC, Lambert W, Singler JM, Tanagho Y, Leandre F, Nevil P, Bertrand D, Claude MS, Bertrand J, Louissaint M, Joanis L, Mukherjee JS, **Goldie SJ**, Salazar JJ, Farmer PE. Factors associated with forced sex among women accessing health services in rural Haiti: implications for the prevention of HIV infection and other sexually transmitted diseases. *Soc Sci Med*. 2005; 60:679-689.
66. Kimmel AD, **Goldie SJ**, Walensky RP, Losina E, Weinstein, MC, Paltiel AD, Zhang H, Freedberg KA. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of combination antiretroviral therapy in HIV-infected patients. *Antivir Ther*. 2005; 10:41-52.
67. Sax PE, Losina E, Weinstein MC, Paltiel AD, **Goldie SJ**, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of Enfuvirtide (ENF) in treatment-experienced patients with advanced HIV disease. *J Acquir Immune Defic Syndr*. 2005; 39:69-77.
68. Kim JJ, Wright TC, **Goldie SJ**. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. *J Natl Cancer Inst*. 2005; 97:888-895.
69. Schackman BR, Freedberg KA, **Goldie SJ**, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment in Georgia and Massachusetts. *Health Care Financing Review*. 2005; 26:67-80.
70. Aledort J, Hook E, Weinstein MC, **Goldie SJ**. Cost-effectiveness of gonorrhea screening in urban emergency departments. *Sex Transm Dis*. 2005; 32:425-436
71. Yazdanpanah Y, Anglaret X, Losina E, **Goldie SJ**, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA; for the Global AIDS Policy Model Investigators. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire. *AIDS*. 2005; 19:1299-1308.
72. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, **Goldie SJ**, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost effectiveness analysis. *Clin Infect Dis*. 2005; 41:1316-23.
73. Goldhaber-Fiebert JD, Denny LE, De Souza M, Wright TC, Kuhn L, **Goldie SJ**. The costs of reducing loss to follow-up in South African cervical cancer screening. *Cost Eff Resour Alloc*. 2005; 3-11.
74. **Goldie SJ**, Gaffikin L, Goldhaber-Fiebert JD, Gordilla A, Levin C, Mahe C, Wright T. Cost-effectiveness of cervical cancer screening in in Five Developing Countries. *N Engl J Med*. 2005; 353:2158-68.
75. O'Mara J, Fisher JD, **Goldie SJ**, Kim SG, Ferrick KJ, Gross JN, Palma EC. Effects of cardioactive medications on retrograde conduction: continuing relevance for current devices. *J Interv Card Electrophysiol*. 2006; 15:49-55.
76. Korves C, **Goldie SJ**, Murray M. Cost-effectiveness of alternative blood-screening strategies for west nile virus in the United States. *PLoS Med* 2006; 3(2):e21.
77. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, **Goldie SJ**. Cost-effectiveness analysis based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). *J Natl Cancer Inst*. 2006; 98:92-100.

78. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Brenner H, Voigt K, Gibis B, Hölzel D, **Goldie SJ**. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. *Eur J Public Health*. 2006; 16:185-92.
79. Kimmel AD, Losina E, Freedberg KA, **Goldie SJ**. Diagnostic tests in HIV management: A review of clinical and laboratory strategies to monitor HIV-infected individuals in less developed countries. *Bull World Health Organ*. 2006; 84:581-8.
80. Hu D, Hook EW III, **Goldie SJ**. The impact of natural history parameters on the cost-effectiveness of chlamydia trachomatis screening strategies. *Sex Transm Dis*. 2006; 33:428-36.
81. Korves C, **Goldie SJ**, Murray MB. Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy. *Clin Infect Dis* 2006 Aug 15, 43:490-3.
82. Roux L, Kuntz KM, Donaldson C, **Goldie SJ**. Economic evaluation of weight loss interventions in overweight and obese women. *Obesity (Silver Spring)*. 2006 Jun, 14:1093-106.
83. Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, **Goldie SJ**, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. *S Afr Med J*. 2006 Jun; 96:526-9.
84. Goldhaber-Fiebert JD, **Goldie SJ**. Estimating the cost of cervical cancer screening in five developing countries. *Cost Eff Resour Alloc*. 2006 Aug 3; 4:13. doi:10.1186/1478-7547-4-13.
85. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu, HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. *N Engl J Med*. 2006; 355:1141-53.
86. **Goldie SJ**, Goldhaber-Fiebert, Garnett G. Public health policy for cervical cancer prevention: role of decision science, economic evaluation, and mathematical modeling. Towards a new paradigm in cervical cancer prevention. *Vaccine*. 2006; 24:S155-S163.
87. **Goldie SJ**, Kim JJ, Myers E. Cost-effectiveness of cervical cancer screening. *Vaccine*. 2006;24; S164-S170.
88. Garnett G, Kim JJ, French K, **Goldie SJ**. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. *Vaccine*. 2006; 24:S178-S186.
89. Kim JJ, Salomon J, Weinstein M, **Goldie SJ**. Packaging health services when resources are limited: the example of a single cervical cancer screening visit. *PLoS Medicine*. 2006; 3:e434.
90. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, **Goldie SJ**, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2006 Dec 1; 43(Suppl 1):S113-S118.
91. Kwon JS, Carey MS, **Goldie SJ**, Kim JJ. Cost-Effectiveness Analysis of Treatment Strategies for Stage I and II Endometrial Cancer C. *J Obstet Gynaec Canada*. 2007; 29(2):131-139.
92. Campos NG, Salomon JA, Nunes DP, Samet JH, Freedberg KA, **Goldie SJ**. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with human immunodeficiency virus. *Am J Med*. 2007 Mar; 120(3):272-9.
93. Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Toure S, Divi N, Anglaret X, **Goldie SJ**, Freedberg KA. HIV drug resistance surveillance for prioritizing treatment in resource limited settings. *AIDS*. 2007 May 11; 21(8):973-82.
94. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, **Goldie SJ**. Multiparameter calibration of a natural history model of cervical cancer. *Am J Epidemiol*. 2007 Jul 15; 166(2):137-50.
95. **Goldie SJ**, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MK, Xavier Bosch F, de

- Sanjose S, Franco EL. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. *Vaccine*. 2007 Aug 14; 25(33):6257-6270.
96. Hu D, Bertozzi SM, Gakidou E, Sweet S, **Goldie SJ**. The costs, benefits and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. *PLoS ONE*. 2007 2(1):e750.
 97. Kim JJ, Andres-Beck B, **Goldie SJ**. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. *Br J Cancer*. 2007 Nov 5; 97(9):1322-8.
 98. Kim SY, Salomon JA, **Goldie SJ**. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness and affordability curves. *Bull World Health Organ*. 2007 Nov; 85(11):833-42.
 99. Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, **Goldie SJ**, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model based approach. *HIV Med*. 2007 Oct; 8(7):439-50.
 100. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, **Goldie SJ**, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, Garcia F. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. *CA Cancer J Clin*. 2007; 57(1):7-28.
 101. Agosti JM and **Goldie SJ**. Introducing HPV Vaccine in Developing Countries – Key Challenges and Issues. *NEJM*. 2007 May 10; 356(19):1908-1910.
 102. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, **Goldie SJ**, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. *Popul Health Metr*. 2007 Oct 29; 5(1):11.
 103. Cutts FT, Franceschi S, **Goldie SJ**, Castellsague X, de Sanjose S, Garnett G, Edmunds J, Claeys P, Goldenthal K, Harper D, Markowitz L. Human papillomavirus and HPV vaccines: a review. *Bull WHO*. 2007; 85(9):719-26.
 104. Kim SY, **Goldie SJ**. Cost-Effectiveness Analyses of Vaccination Programmes: A Focused Review of Modelling Approaches. *Pharmacoeconomics*. 2008; 26(3):191-215.
 105. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, **Goldie SJ**. Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. *J Natl Cancer Inst*. 2008 Mar 5; 100(5):308-20.
 106. Hu D, **Goldie SJ**. The economic burden of noncervical human papillomavirus disease in the United States. *Am J Obstet Gynecol*. 2008 May; 198(5):500.e1-7.
 107. Kim JJ, Kobus KE, Diaz M, O'Shea M, Minh HV, **Goldie SJ**. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. *Vaccine*. 2008 Jul 29; 26(32):4015-24.
 108. **Goldie SJ**, O'Shea MK, Campos NG, Diaz-Sanchis M, Sweet SJ, Kim SY. Health and Economic Outcomes of HPV 16,18 Vaccination in 72 GAVI-eligible countries. *Vaccine*. 2008 Jul 29; 26(32):4080-93.
 109. Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, Bosch FX, **Goldie SJ**. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. *British Journal of Cancer*. 2008 Jul 22; 99(2):230-8.
 110. Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY, **Goldie SJ**. Development of an empirically calibrated model of gastric cancer in two high-risk countries. *Cancer Epidemiology, Biomarkers & Prevention*. 2008 May; 17(5):1179-87.

111. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, **Goldie SJ**, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA, and the CEPAC-International Investigators. Scaling up anti-retroviral therapy in South Africa: the impact of speed on survival. *Journal of Infectious Diseases*. 2008 May 1; 197(9):1324-32.
112. Rydzak C, **Goldie SJ**. Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. *Sexually Transmitted Diseases*. 2008 Sep; 35(9):775-84.
113. Kim JJ, **Goldie SJ**. Health and economic implications of HPV vaccination in the United States. *N Engl J Med*. 2008 Aug 21; 359(8):821-32.
114. **Goldie SJ**, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. *Vaccine*. 2008 Aug 19; 26(S11):L59-L72.
115. **Goldie SJ**, Diaz M, Kim SY, Levin CE, Minh HV, Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. *Vaccine*. 2008 Aug 19; 26(S12):M17-M29.
116. Kim JJ, Brisson M, Edmunds WJ, **Goldie SJ**. Modeling cervical cancer prevention in developed countries. *Vaccine*. 2008 Aug 19; 26(S10):K76-K86.
117. Munoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, **Goldie SJ**, Bosch FX. Recommendations for cervical cancer prevention in Latin America and the Caribbean. *Vaccine*. 2008 Aug 19; 26(S11):L96-L107.
118. Garland SM, Cuzick J, Domingo EJ, **Goldie SJ**, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX. Recommendations for cervical cancer prevention in Asia Pacific. *Vaccine*. 2008 Aug 19; 26(S12):M89-M98.
119. Andrus JK, Lewis MJ, **Goldie SJ**, Garcia PJ, Winkler JL, Ruiz-Matus C, de Quadros CA. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. *Vaccine*. 2008 Aug 19; 26(S11):L80-L87.
120. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, **Goldie SJ**. Tradeoffs in cervical cancer prevention: balancing benefits and risks. *Arch Intern Med*. 2008; 168(17):1881-9.
121. Andersson KL, Salomon JA, Chung RT, **Goldie SJ**. Cost-effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2008; 6(12):1418-1424.
122. **Goldie SJ**, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. *Reprod Health Matters*. 2008; 16(32):86-96.
123. Stout NK, **Goldie SJ**. Keeping the noise down: Common random numbers for disease simulation modeling. *Health Care Management Science*. 2008; 11(4):399-406. doi: 10.1007/s10729-008-9067-6.
124. Kim SY, **Goldie SJ**, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. *BMC Public Health*. 2009; 9(1):29.
125. Yeh JM, Kuntz KM, Ezzati M, **Goldie SJ**. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. *Int J Cancer*. 2009; 124(1):157-66.
126. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, **Goldie SJ**, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, Schrag D, Schulman KA, Scott J. A health services research agenda for cellular, molecular, and genomic technologies in cancer care. *Public Health Genomics*. 2009; 12(4):233-44.
127. Hu D, Grossman D, Levin C, Blanchard K, **Goldie SJ**. Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City. *BJOG*. 2009; 116(6):768-79.
128. Goldhaber-Fiebert JD, Denny LA, De Souza M, Kuhn L, **Goldie SJ**. Program spending to in-

- crease adherence: South African cervical cancer screening. *PLoS ONE* 2009; 4(5):e5691.
129. Kim JJ, **Goldie SJ**. Cost-effectiveness of including boys in a human papillomavirus (HPV) vaccination program in the United States. *BMJ*. 2009; 339:b3884.
 130. Kim JJ, Ortendahl J, **Goldie SJ**. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. *Ann Intern Med*. 2009; 151(8):538-45.
 131. Yeh JM, **Goldie SJ**, Kuntz KM, Ezzati M. Effects of *Helicobacter pylori* infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. *Cancer Causes Contro*. 2009; 20(10):2021-9.
 132. **Goldie SJ**, Sweet S, Carvalho N, Natchu UCM, Hu D, 2010 Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. *PLoS Med*. 7(4): e1000264. doi:10.1371/journal.pmed.1000264.
 133. McCabe CJ, **Goldie SJ**, Fisman DN. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women. *PLoS One*. 2010 Apr 13; 5(4):e10154.
 134. Kimmel AD, Weinstein MC, Anglaret X, **Goldie SJ**, Losina E, Yazdanpanah Y, Messou E, Cotich K, Walensky RP, Freedberg KA, for the CEPAC International investigators. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. *J Acquir Immune Defic Syndr*. 2010; 54(3):258-68.
 135. Yeh JM, Nekhlyudov L, **Goldie SJ**, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. *Ann Intern Med*. 2010; 152:409-417.
 136. Goldhaber-Fiebert JD, Stout NK, **Goldie SJ**. Empirically evaluating decision-analytic models. *Value in Health*. 2010;13:667-74.
 137. Levin CE, Sellors J, Shi JF, Ma L, Qiao YL, Ortendahl J, O'Shea MK, **Goldie SJ**. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. *Int J Cancer*. 2010;127:1404-11.
 138. Kim SY, Sweet S, Slichter D, **Goldie SJ**. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. *BMC Public Health*. 2010 May 14; 10(1):253.
 139. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. *Cancer* 2010;116:2941-53.
 140. Kim SY, **Goldie SJ**, Salomon JA. Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam. *Med Decis Making*. 2010;30:5.
 141. Diaz M, de Sanjose S, Ortendahl J, O'Shea M, **Goldie SJ**, Bosch FX, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. *Eur J Cancer*. 2010;46:2973-85.
 142. Hu D, Grossman D, Levin C, Blanchard K, Adanu R, **Goldie SJ**. Cost-effectiveness analysis of unsafe abortion and alternative first-trimester pregnancy termination strategies in Nigeria and Ghana. *African Journal of Reproductive Health*. 2010;14(2):85.
 143. Ryzdak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, **Goldie SJ**. Assessing the performance of a computer-based policy model of HIV and AIDS *PLoS One*. 2010;5:9.
 144. Price RA, **Goldie SJ**. Association between physician specialty and uptake of new medical technologies: HPV tests in Florida Medicaid. *J Gen Intern Med*. 2010;25(11):1178-85.
 145. Kim SY, Lee G, **Goldie SJ**. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. *BMC Infect Dis*. 2010;10.
 146. Profit J, Lee D, Zupancic JA, Papile L, Gutierrez C, **Goldie SJ**, Gonzalez-Pier E, Salomon JA.

- Clinical benefits, costs and cost-effectiveness of neonatal intensive care in Mexico. *PLoS Med.* 2010;7:e1000379.
147. Price RA, Frank RG, Cleary PD, **Goldie SJ**. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. *Medical Care.* 2011;49:132-38. doi: 10.1097/MLR.0b013e3181f81c63
 148. Hsu H, Rydzak C, Cotich K, Wang B, Sax P, Losina E, Freedberg K, **Goldie SJ**, Lu Z, Walensky R, CEPAC International Investigators. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. *HIV Med.* 2011;12:97-108.
 149. **Goldie SJ**, Daniels N. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. *JNCI.* 2011;103:1373-86. doi: 10.1093/jnci/djr303.
 150. Kim SY, Sweet S, Chang J, **Goldie SJ**. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. *BMC Infectious Diseases.* 2011;11:174.
 151. Kim SY, Choi Y, Mason P, Rusakaniko S, **Goldie SJ**. Potential Impact of Reactive Vaccination in Controlling Cholera Outbreaks: an Exploratory Analysis Using a Zimbabwean Experience. *S Afr Med J.* 2011;101:659-64.
 152. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, **Goldie SJ**. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. *Int J Cancer.* 2012;130:2672-2684. doi: 10.1002/ijc.26269.
 153. Carvalho N, **Goldie SJ**, Salehi A. The value of family planning for improving maternal health in rural Afghanistan: The example of Kandahar. *Afghanistan Journal of Public Health.* 2012;1:12-19.
 154. **Goldie SJ**, Levin C, Mosqueira-Lovon N, Oretendahl J, Kim J, O'Shea M, Diaz M, Mendoza Araujo M. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. *Rev Panam Salud Publica.* 2012;32:6:426-434.
 155. Erim D, Resch S, **Goldie SJ**. Assessing health and economic outcomes of interventions to reduce pregnancy-related mortality in Nigeria. *BMC Public Health.* 2012;12:786.
 156. Kimmel A, Resch S, Anglaret X, Daniels N, **Goldie SJ**, Danel C, Wong A, Freedberg K, Weinstein M. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. *Cost Eff Resour Alloc.* 2012;101:1-12.
 157. **Goldie SJ**, O'Shea M, Kim JJ. Finding consensus on cervical cancer prevention. *Am J Public Health.* 2012 Jun;102(6):1050-1. Epub 2012 Apr 19.
 158. Carvalho N, Salehi A, **Goldie SJ**. National and sub-national analysis of the health benefits and cost-effectiveness of strategies to reduce maternal mortality in Afghanistan. *Health Policy and Planning.* 2013;28:1:62-74.
 159. Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, Ward Z, **Goldie SJ**. Contributions of *H. pylori* and smoking trends to US incidence of intestinal-type Noncardia Gastric Adenocarcinoma; A microsimulation model. *PLoS Med.* 2013 10(5): e1001451. doi:10.1371/journal.pmed.1001451.
 160. van den Hende M, Boa R, Redeker A, Kwappenberg KMC, Kuhn L, **Goldie SJ**, Denny L, van der Burg SH, Wright TC, Offringa R. Evaluation of HPV E6-specific T-cell immunity in Haitian and South African women in relation to clearance or persistence of cervical HPV infections. (Under review)
 161. Lee LA, Franzel L, Atwell J, Datta D, Friberg IK, **Goldie SJ**, Reef SE, Schwalbe N, Simons E, Strebel PM, Sweet S, Suraratdecha C, Tam Y, Vynnycky E, Walker N, Walker DG, Hansen PM.

- The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance. *Vaccine*. 2013 Apr 18;31 Suppl 2:B61–72. doi: 10.1016/j.vaccine.2012.11.035.
162. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo F, Evans D, Feachem RG, Frenk J, Ghosh G, **Goldie SJ**, Guo Y, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK, Ncube M, Pablos-Mendez A, Reddy KS, Saxenian H, Soucat A, Ulltveit-Moe KH, Yamey G. Global health 2035: a world converging within a generation. *Lancet*. 2013 Dec 7;382(9908):1898–955.
 163. Edge JS, Ramirez CL, Reardon CS, Saljuqi AT, **Goldie SJ**. Global Health 2035: The Afghanistan Context. *Afghanistan Journal of Public Health*. 2014;2:37–43.
 164. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo F, Evans D, Feachem RG, Frenk J, Ghosh G, **Goldie SJ**, Guo Y, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK, Ncube M, Pablos-Mendez A, Reddy KS, Saxenian H, Soucat A, Ulltveit-Moe KH, Yamey G. Global health 2035: a world converging within a generation. *Salud Publica Mex*. 2015 Sep-Oct;57(5):444–67 (article in Spanish)
 165. Chu P, Gotink RA, Yeh GY, **Goldie SJ**, Hunink MGM. The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. *European Journal of Preventive Cardiology*. 2016 Feb;23(3):291–307. doi: 10.1177/2047487314562741. Epub 2014 Dec 15.
 166. Yeh JM, Hur C, Ward Z, Schrag D, **Goldie SJ**. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technology: a cost-effectiveness analysis. *Gut*. 2016 Apr;65(4):563–74. doi: 10.1136/gutjnl-2014-308588. Epub 2015 Mar 16.
 167. Chu P, Pandya A, Salomon JA, **Goldie SJ**, Hunink MG. Comparative Effectiveness of Personalized Lifestyle Management Strategies for Cardiovascular Disease Risk Reduction. *J Am Heart Assoc*. 2016 Mar 29;4(3):e002737. doi: 10.1161/JAHA.115.002737.
 168. Ozawa S, Clark S, Portnoy A, Grewal S, Stack ML, Sinha A, Mirelman A, Franklin H, Friberg IK, Tam Y, Walker N, Clark A, Ferrari M, Suraratdecha C, Sweet S, **Goldie SJ**, Garske T, Li M, Hansen PM, Johnson HL, Walker D. Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001–2020. *Bulletin of the World Health Organization*. 2017 Sep 1;95(9):629–638. <http://dx.doi.org/10.2471/BLT.16.178475> Epub 2017 June 27
 169. Chu P, Pandya A, Gaziano TA, Sy S, Salomon J, **Goldie SJ**, Hunink MG. Cost-effectiveness of aerobic exercise and yoga for primary prevention of cardiovascular disease (under review)
 170. Watkins D, Yamey G, Schäferhoff M, Adeyi O, Alleyne G, Alwan A, Berkley S, Feachem R, Frenk J, Ghosh G, **Goldie SJ**, Guo Y, Gupta S, Knaul F, Kruk M, Nugent R, Ogbuaji O, Qi J, Reddy S, Saxenian H, Soucat A, Jamison D, Summers L. Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. *Lancet*. 2018; 392: 1434–60.

Chapters

1. Wright TC, Denny L, Kuhn L, **Goldie SJ**. Use of visual screening methods for cervical cancer screening in resource poor settings: A comprehensive review. Chapter 5. *Clinics in Obstetrics and Gynecology of North America*. 2002;29:701–34.
2. **Goldie SJ**, Corso, P. Decision Analytic Models in Public Health, Prevention effectiveness: a guide to decision analysis and economic evaluation. Chapter 4. Oxford: Oxford University Press, Inc. 2003.
3. Brown M, **Goldie SJ**, Draisma G, Harford J, Lipscomb J. Health service interventions for cancer control in developing countries. *Disease Control Priorities in Developing Countries (2nd Edition)*, New York: Oxford University Press, 2006:569–590.

4. **Goldie SJ.** A Public Health Approach to Cervical Cancer Control, Considerations of Screening and Vaccination Strategies. *Int J Gynaecol Obstet.* 2006;94 Suppl 1:S95-105.

Technical Reports

1. **Goldie SJ,** Grima D, Kohli M, Wright TC, Franco E. Assessing the potential clinical benefits of a prophylactic HPV 16/18 vaccine: using a comprehensive natural history model of type-specific HPV and cervical cancer to evaluate surrogate clinical trial endpoints (Technical Report to the FDA, October 2001).
2. **Goldie SJ,** Sweet S, Goldhaber-Fiebert. Assessing the potential cost-effectiveness of an HPV 16/18 vaccine in Tanzania (Technical Report to the World Health Organization, 2005).
3. Constenla D, **Goldie SJ,** Alvis N, O'Shea M, Sweet S, Valenzuela M, Cavada G, de la Hoz F, Koumans E, Labbo MN, Koss C, Posso H. Health and economic outcomes of human papillomavirus (HPV) vaccination in selected countries in Latin America: a preliminary economic analysis. (Report to the Sabin Vaccine Institute, 2008).
4. **Goldie SJ,** Levin C, O'Shea M, Ortendahl J, Sweet S, Sharma M, Sy S, Diaz M, Kim JJ. Investment in the future of girls in Peru: report of HPV 16,18 vaccination of adolescent girls in Peru. (Report to the Peru Ministry of Health, 2009).
5. Hu D, Bertozzi SM, Gakidou E, Sweet S, **Goldie SJ.** Supplemental Appendix: The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico.
6. **Goldie SJ,** Sweet S, Carvalho N, Natchu UCM, Hu D. Supplemental Appendix: Alternate strategies to reduce maternal mortality in India: a cost-effectiveness analysis.
7. Carvalho N, Salehi AS, **Goldie SJ.** Supplemental Appendix: Cost-effectiveness analysis of strategies to reduce maternal mortality in Afghanistan.
8. **Goldie SJ,** Sweet S, Nieder Z, Shankar A, Fawzi W. Supplemental Appendix: Cost-effectiveness analysis of strategies to reduce maternal mortality in Tanzania.
9. Erim D, Resch S, **Goldie SJ.** Technical Appendix: Cost-effectiveness analysis of strategies to reduce maternal mortality in Nigeria.
10. Erim D, Resch S, **Goldie SJ.** Technical Brief on Maternal Mortality Planning: Ministry of Health, Nigeria.
11. **Goldie SJ.** Reducing deaths from maternal mortality in India, Nigeria, Afghanistan: Overview of decision science approach. Supplement: A preliminary analysis of NASG.

Reviews, Letters, Technical Comments

1. **Goldie SJ,** Waxman AB. Cytomegalovirus as a primary pulmonary pathogen in AIDS. *Chest* 1997; 112:861.
2. Angoff N, **Goldie SJ.** Teaching care of terminal disease: A primary care perspective. *Conn Med.* 1998 Mar; 62(3):139-42.
3. Yazdanpanah Y, **Goldie SJ,** Salamon R, Mouton Y, Freedberg KA. Are European-specific guidelines needed for the prevention of opportunistic infections in persons infected with human immunodeficiency virus? *Lancet.* 1999; 354:1305-6.
4. USPHS/IDSA Prevention of Opportunistic Infections Working Group (**S Goldie,** member). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR.* 1999; 48:1-65.
5. **Goldie SJ.** Preventing cervical and anal cancer in HIV-positive women and men: using a disease-specific model to develop clinical guidelines. *Risk in Perspective.* February 2000; 8(2):1-

- 5.
6. Neumann PJ, **Goldie SJ**, Weinstein MC. Preference-based measures in economic evaluation in health care. *Ann. Rev. Public Health.* 2000; 21:1-25.
7. **Goldie SJ**, Wright TC. HPV DNA testing- Technical Comments. *Science.* 2001; 290:1651a.
8. Freedberg KF, Losina E, Weinstein MC, Paltiel AD, **Goldie SJ**. The cost-effectiveness of combination antiretroviral therapy for HIV disease. *N Engl J Med.* 2001; 345:68-9.
9. Hagen MD, Garber AM, **Goldie SJ**, Lafat JE, Mandelblatt J, Meltzer D, Neumann P, Siegel JE, Sox HC, Tsevat J. Does cost-effectiveness analysis make a difference? Lessons from pap smears. *Med Decis Making.* 2001; 21:307-23.
10. **Goldie SJ**. Cost-effectiveness of alternative screening strategies to decrease cervical cancer mortality in low resource settings. *Risk in Perspective.* August 2001.
11. **Goldie SJ**, Kuhn LK, Denny L, Pollack A, Wright TC. Cervical cancer screening in developing countries. *JAMA.* 2001; 286:3080-1.
12. Fisman DN, Reilly DT, Karchmer A, **Goldie SJ**. Response to mathematical modeling for infected total hip arthroplasty in the elderly. *Clin Infect Dis.* 2002; 34:871-874.
13. Kim J, **Goldie SJ**. New technology provides an additional option for women with equivocal Pap smears. *Risk in Perspective.* October 2002; 10(4):1-6.
14. Salomon J, **Goldie SJ**. Cost-effectiveness of treatment for chronic hepatitis C virus in an evolving patient population. *JAMA.* 2003; 290:1994.
15. Hu D, Hook E, **Goldie SJ**. Relative cost effectiveness of different tests for Chlamydia trachomatis. *Ann Intern Med.* 2005; 142:308-309.
16. Suba EJ, Frable WJ, Raab SS, **Goldie SJ**. Cost-effectiveness of cervical-cancer screening in developing countries. *N Engl J Med.* 2006; 354:1535-1536.
17. Campos NG, **Goldie SJ**. HPV Genotypes in Women with HIV. *AIDS Clin Care* 2006; 18:91.
18. **Goldie SJ**. Preventing Cervical Cancer Deaths: How to save 4 million lives in 10 years. Disease Control Priorities Project. 2007 Jul 20. <http://www.dcp2.org/features/51>.
19. Miller NB, Raychaudhuri G, Toerner JG, Suba EJ, Raab SS, the Viet/American Cervical Cancer Prevention Project, Garland SG, Koutsky LA, Sawaya GF, Smith-McCune K, Agosti JM, **Goldie SJ**. Human papillomavirus vaccine. *N Engl J Med.* 2007; 357:1154-6.
20. Kwon J, Carey M, **Goldie SJ**, Kim J. Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. *Obstet Gynecol.* 2007; 110(4):933.
21. Goldhaber-Fiebert JD, **Goldie SJ**. Response to cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. *J Natl Cancer Inst.* 2008; 100(22):1654-1655.
22. **Goldie SJ**, O'Shea M, Kim JJ. Response to: Maine, et al., Finding consensus on cervical cancer prevention. *AJPH.* 2012; 102:1050-1051.
23. **Goldie SJ**. Strengthening Afghanistan's health system: challenges, progress, and opportunities. *Afghanistan Journal of Public Health.* 2012;1:2-3.
24. **Goldie SJ**. Celebrating Milestones, Looking to the Future. *Afghanistan Journal of Public Health* 2014;2:5-7